Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5097MR)

This product GTTS-WQ5097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5097MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10966MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ11654MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ9388MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ11990MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ5878MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ11421MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ6911MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5207MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW